Nora Pharma reels in $25M for women’s health
Nora Pharmaceuticals, developer of women’s reproductive health drugs and devices, brought in $25 million in first round financing from Burrill & Co., Prospect Venture Partners and Vivo Ventures. The San Francisco-based company is still pretty stealthy (it doesn’t even have a website). It did release that it has some products, but did not specify further.
There is a lot of investor interest in this area of healthcare right now, reports VentureWire. Swiss startup Lumavita, for example, just received $15.4 million to develop treatments for conditions caused by HPV in women. Agile Therapeutics brought in $17.6 million last year to continue work on a once-weekly contraceptive patch. And Interlace Medical raised $7 million for gynecological instruments.
Next Story: Envia raises $3.2M for lithium ion batteries
Previous Story: Youcalc democratizes analytics with “smart widgets”
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.